Process for making dry and stable hemostatic compositions

Patent metadata

Field	Value
Publication number	US-10994045-B2
Application number	US-201916272302-A
Country	US
Kind code	B2
Filing date	Feb 11, 2019
Priority date	Jun 1, 2010
Publication date	May 4, 2021
Grant date	May 4, 2021

Abstract

Described is a process for making a dry and stable hemostatic composition, said process comprising
a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container,
c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container,
d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.

First claim

What is claimed is:

1. A process for making a dry and stable hemostatic composition, said process comprising
a) mixing in a solid state a first component comprising a dry preparation of a coagulation inducing agent and a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis to obtain said first component and said second component in a combined form,
b) filling said first component and said second component in the combined form into a final container so as to obtain a dry mixture in said final container, and
c) finishing the final container to a storable pharmaceutical device containing said first component and said second component in the dry mixture as a dry and stable hemostatic composition.

2. The process according to claim 1 , wherein steps a) and b) are performed under aseptic conditions.

3. The process according to claim 1 , wherein the dry preparation of a coagulation inducing agent is prepared by lyophilizing an aqueous preparation of a coagulation inducing agent.

4. The process according to claim 1 , wherein step c) comprises an ethylene oxide sterilization step or a treatment with ionizing irradiation.

5. The process according to claim 1 , wherein the first component is a dry thrombin preparation.

6. The process according to claim 1 , wherein the first component is a dry particulate thrombin preparation.

7. The process according to claim 1 , wherein the first component is a dry thrombin powder.

8. The process according to claim 1 , wherein the first component contains thrombin obtained by spray drying or aseptic spray drying.

9. The process according to claim 1 , wherein the final container is a syringe.

10. The process according to claim 9 , wherein the syringe is a syringe finished together with a diluent syringe with a pharmaceutically acceptable diluent for reconstituting said dry and stable hemostatic composition.

11. The process according to claim 1 , wherein the first component comprises human thrombin.

12. The process according to claim 1 , wherein the first component comprises recombinant human thrombin.

13. The process according to claim 1 , wherein the biocompatible polymer suitable for use in hemostasis contains a protein selected from the group consisting of gelatin, soluble collagen, albumin, hemoglobin, fibrinogen, fibrin, casein, fibronectin, elastin, keratin, and laminin; or derivatives or combinations thereof.

14. The process according to claim 1 , wherein the biocompatible polymer suitable for use in hemostasis contains a polysaccharide selected from the group consisting of glycosaminoglycans, starch derivatives, cellulose derivatives, hemicellulose derivatives, xylan, agarose, alginate, and chitosan; or derivatives or combinations thereof.

15. The process according to claim 1 , wherein the biocompatible polymer suitable for use in hemostasis contains a polymer selected from the group consisting of polyacrylates, polymethacrylates, polyacrylamides, polyvinyl resins, polylactide-glycolides, polycaprolactones, and polyoxyethlenes; and derivatives and combinations thereof.

16. The process according to claim 1 , wherein the biocompatible polymer suitable for use in hemostasis contains a crosslinked polysaccharide, a crosslinked protein, or a crosslinked non-biologic polymer; or mixtures thereof.

17. The process according to claim 1 , wherein the biocompatible polymer suitable for use in hemostasis is a particulate material.

18. The process according to claim 1 , wherein the biocompatible polymer suitable for use in hemostasis is a granular material.

19. The process according to claim 1 , wherein the biocompatible polymer suitable for use in hemostasis is a cross-linked gelatin.

20. The process according to claim 1 , wherein the final container further contains an amount of a stabilizer effective to inhibit modification of the polymer when exposed to the sterilizing radiation, preferably ascorbic acid, sodium ascorbate, other salts of ascorbic acid, or an antioxidant.

Assignees

• Baxter Int
• Baxter Healthcare Sa

Inventors

• Goessl Andreas
• Osawa Atsushi Edward
• Reich Cary J

Classifications

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• Y10T428/13

  Hollow or container type article [e.g., tube, vase, etc.] · CPC title

• A61K38/4833

  Thrombin (3.4.21.5) · CPC title

• A61K9/1658

  Proteins, e.g. albumin, gelatin · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title